Latest low-risk prostate cancer Stories
New research from The University of Texas MD Anderson Cancer Center is shedding light on the important role a diagnosing urologist plays in whether older men with low-risk prostate cancer receive treatment for their disease, and if so, the type of treatment they receive as a result.
The most comprehensive retrospective study ever conducted comparing how the major types of prostate cancer treatments stack up to each other in terms of saving lives and cost effectiveness is reported this week by a team of researchers at the University of California, San Francisco (UCSF).
The prostate-specific antigen test, commonly known as the PSA test, is valuable in predicting which men should have biopsies and which are likely to be diagnosed with low-risk prostate cancer, a Mayo Clinic study has found.
The initial treatment strategy, active surveillance, for 65 year old men with low-risk prostate cancer showed a higher quality of life when compared to an initial treatment like radical prostatectomy.
In a study that compared initial treatment strategies for low-risk prostate cancer among men 65 years old, active surveillance showed higher measures on quality of life compared to an initial treatment such as radical prostatectomy, although the optimal strategy was highly dependent on individual patient preferences for surveillance or treatment.
Active surveillance or watchful waiting might be sufficient treatment for patients with prostate cancer that has a low risk of progression, according to a new study published online June 18 in The Journal of the National Cancer Institute.
Institute for Clinical and Economic Review summary incorporates findings from 3 separate appraisals of 6 treatment options.
By Amy Norton NEW YORK (Reuters Health) - Men with early, slow-growing prostate cancer may safely wait up to six months before starting treatment, a new study suggests.